A Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Target Engagement of BMS-986147 in Healthy Subjects

A Randomized, Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Target Engagement of BMS-986147 in Healthy Subjects

This is the first clinical study with the BMS-986147 compound in healthy subjects. The purpose of this study is to guide the dose range and dose frequency for future studies with BMS-986147 and will provide guidelines for selection of a potentially effective dose in patients.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Healthy men and women, ages 18 to 45 years
• Subjects must not have clinically significant deviation from normal: medical history, physical examination, ECGs and laboratory evaluations
• Women of child bearing potential are eligible for enrollment.
• Women must have a negative pregnancy test

Exclusion Criteria:

• Evidence of organ dysfunction
• Any significant acute or chronic medical illness
• Inability to: tolerate oral medications, be venipunctured